Guangzhou Baiyunshan Pharmaceutical Holdings Company (HK:0874) has released an update.
Guangzhou Baiyunshan Pharmaceutical Holdings Company has revised its partnership agreement to include the Nansha Science and Technology Innovation Master Fund as a new partner in the WBA GP Fund, without changing the fund’s capital contribution terms. This transaction is categorized as a connected transaction under Hong Kong Listing Rules and has been approved by the Board, thus exempt from requiring independent shareholders’ approval but still subject to specific reporting and announcement requirements.
For further insights into HK:0874 stock, check out TipRanks’ Stock Analysis page.
